The BAK1 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout population of DLD-1 colorectal adenocarcinoma cells, disrupting the pro-apoptotic gene BAK1. This heterogeneous pool harbors loss-of-function BAK1 alleles, preserving diversity ideal for studies needing representative gene disruption without clonal bias. The cells lack BAK1-dependent mitochondrial outer membrane permeabilization, providing a robust model to probe apoptosis signaling.
DLD-1 is a colorectal carcinoma line from a male patient, carrying mutations in APC, TP53 (p53), and KRAS??key drivers of colorectal tumorigenesis. This adherent epithelial line is widely used to investigate colorectal cancer biology, drug response, and resistance, retaining active Wnt/??-catenin and MAPK pathways.
BAK1 encodes the pro-apoptotic BCL-2 family effector BAK, which oligomerizes at the mitochondrial outer membrane following activation by BH3-only proteins (BIM, BID, PUMA, NOXA). Oligomeric BAK pores release cytochrome c, triggering apoptosome assembly (APAF1, caspase-9) and caspase-3 activation. Anti-apoptotic BCL-2 members (BCL-2, BCL-XL, MCL-1) restrain BAK1 by direct binding or sequestration of BH3-only activators. BAK1 activity is also regulated upstream by p53 and interacts with VDAC and BAX. Thus, BAK1 is a critical execution point in intrinsic apoptosis, dysregulated in many cancers.
In DLD-1, BAK1 knockout exacerbates apoptosis resistance imposed by mutant p53, creating a model of multi-layered apoptotic blockade pertinent to colorectal cancer. This system enables dissection of the relative contributions of BAX vs. BAK1, mapping dependencies on anti-apoptotic BCL-2 family proteins, and evaluating BH3 mimetics that target BCL-2/BCL-XL. Combined with DLD-1??s APC and KRAS mutations, this model recapitulates key features of colorectal cancers evading therapy-induced apoptosis.
Applications span mechanistic apoptosis research, drug sensitivity screening, and mitochondrial functional studies. Assays include Annexin V/PI flow cytometry, JC-1 mitochondrial potential measurement, cytochrome c release, caspase-3/7 activity, and co-immunoprecipitation of BCL-2 family complexes. The polyclonal knockout format supports population-level readouts in high-throughput compound screens, especially for BH3 mimetics. For additional information, contact Ascent Research.
